UDP-glucuronosyltransferase 1A1 (UGT1A1) is an enzyme that is found in the endoplasmic reticulum membrane and can reportedly have a large number of amino acid substitutions that result in the reduction of glucuronidation capacity. For example, adverse drug reactions when patients receive CPT-11 (irinotecan) such as in cancer chemotherapy are caused by amino acid substitutions in UGT1A1. We previously found that the extent of the docking when the hydroxyl residue of bilirubin was oriented toward UDP-glucuronic acid correlated with in vitro conjugation capacity. In this study, we analyzed the conformation of mutant UGT1A1s by means of structural optimization with water and lipid bilayers instead of the optimization in vacuo that we used in our previous study. We then derived a mathematical model that can predict the conjugation capacities of mutant UGT1A1s by using results of substrate docking in silico and results of in vitro analysis of glucuronidation of acetaminophen and 17β-estradiol by UGT1A1s. This experimental procedure showed that the in silico conjugation capacities of other mutant UGT1A1s with bilirubin or SN-38 were similar to reported in vitro conjugation capacities. Our results suggest that this experimental procedure described herein can correctly predict the conjugation capacities of mutant UGT1A1s and any substrate.
Introduction
Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) is a member of the UDP-glucuronosyltransferase 1A enzyme family that is mainly localized in the smooth endoplasmic reticulum in the liver and other tissues [1] . UGT1A1 plays an essential role in the metabolism of a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 about 80 chemical substances including bilirubin and CPT-11 (irinotecan), an anticancer agent [2, 3] . Locuson and Tracy [4] reported on a binding model of UGT1A1 with a coenzyme, UDP-glucuronic acid (UDPGA), whose binding site included the amino acids S38, H173, G308, L355, S375, H376, and G377. In our previous research based on their report, we showed that conjugation proceeded when the hydroxyl residue of bilirubin was oriented toward UDPGA [5] .
Mutations of the UGT1A1 gene have been found in hereditary diseases, such as hyperbilirubinemia, Crigler-Najjar syndrome, and Gilbert syndrome, and at least 70 mutations of this gene have been reported [6] . An adverse reaction to the drug CPT-11 is well known to be associated with mutant UGT1A1 [7] . Major mutations of UGT1A1, especially the UGT1A1 � 6 and UGT1A1 � 28 mutations, are well known to reduce conjugation capacity. The former mutation causes the loss of function in conjugation capacity because of the amino acid substitution of G71R [8] , and the latter induces a quantitative reduction in UGT1A1 gene expression with an increase in the TA repeat from 6 to 7 of the promoter region [9, 10] . CPT-11 is converted to SN-38, an active metabolite, and is then metabolized to become a water-soluble form via glucuronidation of the UGT1A1 enzyme [11] . The risk for CPT-11 toxicity increases with these genetic variants. Today, a genetic test for UGT1A1, especially the UGT1A1 � 6 and UGT1A1 � 28 mutations, is performed before treatment with CPT-11, because use of CPT-11 carries a high risk of adverse effects such as severe neutropenia and diarrhea [12] . In addition, sequencing technology can determine the new amino acid substitutions in UGT1A1, but the glucuronidation capacities of these new mutant UGT1A1s for any substrate, such as SN-38 are usually unknown.
Our molecular simulation analysis that was based on structural biology recently became a powerful tool for studying the biochemical process [13] [14] [15] [16] [17] [18] . Previously, our in silico study of the conjugation process showed that this enzymatic reaction was controlled by the direction of the vicinal hydroxyl group in the substrate [5] . In addition, mathematical models are used for research on biological processes, such as those in drug-drug interactions (DDIs) and drug metabolism [19, 20] .
For our research reported here, we revised our previous molecular simulation analyses, which led to a mathematical model for the conjugation process in order to predict the conjugation capacity for substrates such as bilirubin and SN-38. Coenzyme or substrate docking after structural optimization with water and lipid bilayers was performed to mimic the cellular environment instead of the in vacuo environment that we had used in our previous research. We subsequently developed a mathematical model that we derived from the results from in vitro and in silico analyses. Then we demonstrate here that our mathematical model using the docking results for a specific number of UDPGA-oriented hydroxyl residues of substrates can predict the conjugation capacities of mutant UGT1A1s.
Materials and methods

Construction of the 3D structures of UGT1A1 mutants
The 3D structure of wild-type UGT1A1 was obtained from ModBase [21] (Model ID: 2420a568b0f3d1b1fe06fc34a94eee40). We then added hydrogen atoms to the model structure via PyMOL software [22] , after which we prepared structures of UGT1A1 mutants: G71R, F83L, P229L, P229Q, L233R, I294T, I322V, R336L, H376R, P387S, N400D, and W461R, whose PMIDs in the Protein Model Database [23] are PM0082268, PM0082269, PM0082278, PM0082271, PM0082279, PM0082275, PM0082270, PM0082272, PM0082273, PM0082274, PM0082276, and PM0082277, respectively. We prepared these structures by using molecular operating environment (MOE) software (Chemical Computing Group Inc., Montreal, QC, Canada). Each model structure of the wild-type UGT1A1 and mutant UGT1A1s was embedded in the lipid bilayer using visual molecular dynamics (VMD) software [24] . The location of the bilayer was determined according to a previous report [25] . The transferable intermolecular potential with three points (TIP3P) water model [26] was used for structural optimization of UGT1A1 with water. The minimal distance of a protein atom to the edge of the rectangular water box was 14 Å.
The structural data were then subjected to structural optimization with the AMBER10:EHT force field according to our previous study [27] with slight modifications. We performed energy minimization by means of the molecular mechanics (MM) function of the MOE software by using the steepest descent method until the root mean square gradient was 0.01 kcal/ mol/Å. Then, we used NAMD software to perform molecular dynamics (MD) simulations [28] . The water-protein-bilayer system was gradually heated from 0 K to 310 K during 250 ps. After the heating process, a 10,000-ps production run was performed with the NPT ensemble in a unit of 2 fs. The temperature and pressure of the system were maintained by using the Berendsen coupling algorithm [29] . The SHAKE algorithm [30] was used to constrain water bond geometries. The root mean square deviation (RMSD) from the 10,000-ps molecular dynamics trajectory was analyzed by using VMD (S1A Fig) . Each trajectory was stable after 8000 ps. The quality of each 3D UGT1A1 structure was ascertained via the PROCHECK program [31] , which yielded 1.8% or less in the disallowed regions of the Ramachandran plot (S1B and S1C Fig) . This provided an insight into the correctness of the modeled structures in terms of PROCHECK as reported previously [32] . Each UGT1A1 molecule in the last frame (S2 Fig) was used for the docking analysis.
Docking analysis of UGT1A1 with UDPGA
The docking of UDPGA and each UGT1A1 mutant was analyzed by means of AutoDock4 [33] according to our previous research [5] with slight modifications. The docking site was defined by using the AutoGrid program as a box within 3.8 Å of the amino acids that reportedly interact with UDPGA [4] . This value was determined by means of the sum of the H bond distance (3.2 Å) [34] and the error of the AutoDock (0.6 Å), which we found in our preliminary analysis (S1 Text, S1 Table) . Grids were searched via the Lamarckian genetic algorithm. All other parameters were defined by default settings. All hydrogen atoms were added and water molecules were removed. One hundred different docking runs were performed for each UGT1A1-UDPGA pair.
Docking for each UGT1A1 molecule and the coenzyme UDPGA was performed in the binding mode similar (wild-type) or neighboring (mutants) to that in previous research [4] , which are comprised of amino acids S38, H173, G308, L355, S375, H376, G377, and was defined as the correct binding mode.
Analysis of UGT1A1 docking with acetaminophen (AAP) and 17βestradiol (E2)
We simulated AAP and E2 docking to each UGT1A1 mutant by means of the AutoDock4 program. The 3D structural data of the substrates were obtained from ChemIDplus (registry numbers: 103-90-2 for AAP, 50-28-2 for E2).
The docking site for each of the correctly bound complexes of UGT1A1 and UDPGA was located in front of the bound UDPGA and was sufficiently large to cover the binding site for all substrates that we used in this study. The far boundary of the docking site was defined as 0.5 Å back of the center of the C-O bond between glucuronic acid and UDP of UDPGA.
We performed 100 docking runs for each UGT1A1-substrate pair. We analyzed the number of docking poses with a hydroxyl group oriented toward the coenzyme, that is, the hydroxyl group of the substrate was located within 3.8 Å of the center of the C-O bond between glucuronic acid and UDP of UDPGA, which we had identified as the hydroxyl orientation and the correct binding mode in our previous report [5] . Fig 1A, 1B, 1C and 1D show representative docking results of hydroxyl orientations and other orientations that cannot function in the conjugation reaction. Fig 1E shows the field of the conjugation process in wild-type but the field completely lacks in R336L mutant ( Fig 1F) .
In vitro analysis of glucuronidation for AAP and E2
In vitro conjugation capacities of wild-type UGT1A1 and mutant UGT1A1s were analyzed as described previously [35] with a slight modification. Human UGT1A1 cDNA was obtained from a human liver cDNA library by PCR amplification and was inserted into a pENTR/ D-TOPO vector. Mutations were introduced by using a site-directed mutagenesis method with substitutions at nucleotide positions c.211G>A (p.G71R), c.247T>C (p.F83L), c.964A>G (p.I322V), c.1007G>T (p.R336L), c.1127A>G (p.H376R), and c.1159C>T (p. P387S).
Each wild-type and mutant UGT1A1 sequence was inserted into the expression vector pcDNA-DEST40 Gateway by recombination. The UGT1A1 expression vectors, together with a luciferase reporter vector (pGL3 vector) as an indicator of transfection efficiency, were transfected into COS-7 cells by using Lipofectamine 2000, according to the manufacturer's instructions. The cells were harvested at 48 h after transfection and then homogenized with 70 μL of 0.1 M Tris-HCl (pH 7.5). The cell homogenates were used for UGT1A1 activity and luciferase assays. Luciferase activity was measured with a TD-20/20 luminometer (Promega, Madison, WI, USA) and was used to normalize enzyme activities of the UGT1A1 clones.
Glucuronidation of AAP and E2 was analyzed with the UGT Reaction Mix containing UDPGA (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), according to the manufacturer's instructions. Briefly, a 99-μL sample of the reaction mixture containing 20 μL of Solution A, 8 μL of Solution B, 1 μL of 20 mM AAP or 0.25 mM E2 in ethanol, and 70 μL of cell homogenates was incubated at 37˚C for 2 h. The reaction was terminated by adding 25 μL of acetonitrile for AAP or 25 μL of 94% acetonitrile/6% glacial acetic acid for E2.
After the reaction termination, 5 μL of 1mM p-nitrophenyl β-D-glucuronide (PNPG) or 1 μL of 300 μM ethynylestradiol (EE2) in ethanol was added to the reaction mixture as an internal standard. Then, the reaction mixture was centrifuged and the supernatant was subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) to determine the amount of AAP glucuronide (AAPG) or E2 glucuronide (E2G).
Chromatography was performed with a Shimadzu LC10AD system (Shimadzu, Kyoto, Japan) with a mobile phase consisting of 40% acetonitrile and 25 mM ammonium acetate at a flow rate of 0.3 mL/min for AAP, or 70% methanol, 4.5% of acetonitrile, and 0.15 mM perchloric acid at a flow rate of 0.2 mL/min for E2. The column temperature was maintained at 45˚C. A 15-μL aliquot of each sample was injected onto a Shim-pack CLC-ODS column (4.6 mm I. D. × 15 cm; Shimadzu).
An API-3000TM LC-MS/MS system (Applied Biosystems/MDS SCIEX, Toronto, Canada) was operated with an electrospray ionization source (ESI; TurboIonSpray interface) coupled with the LC system described above. MS scanning was operated in a negative ion mode. Analyst 1.3.1 software was used for equipment control, data acquisition, and analysis. The glucuronide peaks were detected at m/z 326.1/150.0 [precursor ion (Q1)/product ion (Q3)] for AAPG and m/z 447.1/271.1 (Q1/Q3) for E2G. These glucuronide peaks were confirmed because their retention times were the same as those of commercially available authentic standards. With regard to the sensitivity of all assays, the minimal level of detection was 3 ng/assay. Experiments were repeated five times; the coefficient of variation was less than 12%. 
Mathematical model for conjugation capacity of UGT1A1
To establish a mathematical model for glucuronidation by UGT1A1, the enzymatic reaction of UGT1A1 was described by an equation as follows: we first compared in vitro conjugation capacity with the results of docking simulation analyses; we then derived an equation that calculated in vitro conjugation capacity by using the docking results that showed a strong correlation with in vitro conjugation capacity. Different efficiencies of glucuronidation with individual substrates were incorporated into the equation by using the docking results for wild-type UGT1A1.
Verification of the mathematical model by cross-validation
To verify the mathematical model, we used leave-one-out cross-validation with AAP and E2 as substrates as follows: We removed one of the UGT1A1 mutants, determined the constants of the mathematical model by using the rest of the mutants, and then performed calculations to predict the in silico conjugation capacity for the excluded mutant. Finally, we calculated Pearson's correlation coefficient for the in silico and the in vitro conjugation capacities.
Validation of the experimental procedure: Prediction of conjugation capacity of bilirubin and SN-38
To examine the validity of this experimental procedure, we prepared structures of the mutants P229Q, I294T, N400D, W461R, P229L, and L233R for only bilirubin and/or SN-38. The 3D structures of bilirubin and SN-38 were obtained from ChemIDPlus (registry numbers: bilirubin, 635-65-4; SN-38, 86639-52-3) for docking analyses. The docking analyses were performed for the pairs of substrates and UGT1A1 mutants whose in vitro conjugation capacities were reported. To use our mathematical model, docking analyses of bilirubin with UGT1A1s (wild-type, G71R, F83L, P229Q, I294T, N400D, W461R) and SN-38 with UGT1A1s (wild-type, G71R, P229L, P229Q, L233R) were performed in the same manner as those for AAP and E2. The in silico conjugation capacity of each substrate was calculated by means of our mathematical model and then compared with the reported in vitro conjugation capacity. Finally, a correlation plot was analyzed for verification of the mathematical model by using all prediction results for in silico and in vitro data.
Statistical analysis
Statistical analyses were performed with R software (R Core Team 2015). Data are presented as means ± SD. A P value of <0.05 was regarded as statistically significant.
Results
Correlation between the results of docking simulation and in vitro conjugation capacity
To evaluate the results of molecular simulation analyses for the mathematical model for glucuronidation by UGT1A1, we compared the in vitro conjugation capacity of UGT1A1 against AAP and E2 with the results of docking simulation analysis (Fig 2, S2 Table) . A significant correlation existed between the number of hydroxyl orientations of substrate and in vitro conjugation capacity, as we reported previously [5] (Table 1) .
A correlation also existed between the number of hydroxyl orientations of the substrate and in vitro conjugation capacity for the other UGT1A isoforms, UGT1A10 and UGT1A7 (S2 Text, S4 Fig) . However, no significant correlation was found between the binding mode of UDPGA and in vitro conjugation capacity. These results suggest that the hydroxyl orientations of the substrate can be used to derive the mathematical model for glucuronidation by UGT1A1.
Derivation of a mathematical model for estimating the conjugation capacity of UGT1A1
A mathematical model to predict the conjugation capacity of UGT1A1 was derived as described below. Glucuronidation involves the following steps: (i) binding of coenzyme UDPGA to UGT1A1; (ii) binding of substrate to the UGT1A1-UDPGA complex; (iii) conjugation of glucuronic acid with the substrate [36] . The conjugation capacity of UGT1A1 (P C ) can be represented as the product of (i) and (ii):
where C is the contribution of (i) to conjugation capacity and S is the contribution of (ii) to conjugation capacity. The difference in the docking results for each substrate with wild-type UGT1A1 (Fig 2B  and 2C) is represented by the substrate-specific constant σ, and ε represents the in vivo environment of the enzymatic reaction::
The value of ε is set to 0 to predict in vitro conjugation capacity. Because no correlation exists between the correct binding mode of UDPGA and in vitro conjugation capacity (Table 1) , C is replaced with 1:
S is defined as
where S DT is the total number of substrate docking and S DH is the number of hydroxyl orientations of the substrate [5] . Procedure for prediction of conjugation capacity in mutant UGT1A1
Because the enzymatic reaction follows a sigmoid curve [37] , S can be defined by using a sigmoid function:
In addition, we define a variable κ to represent TA repeat polymorphism (UGT1A1 � 28) in the promoter region that is based on the relative values to wild-type/wild-type for each genotype according to the V max values in the previous report: wild-type/wild-type, 16.2 nmol/min/mg; wild-type/ � 28, 12.0 nmol/min/mg; � 28/ � 28, 3.4 nmol/min/mg [10] :
where k ¼ Constant values σ, γ l , μ l , and ε were estimated by minimizing the sum of squared error between in silico conjugation capacity P C and in vitro conjugation capacity V c :
where set M represents the UGT1A1 mutants whose in vitro conjugation capacities are known and correct binding modes of UDPGA were obtained by docking analysis. The relative conjugation capacity of mutant UGT1A1 (percentage of wild-type) is defined by following equation:
In the case of ε = 0, Eq (8) is represented by Eq (9):
S2 
Validation of the mathematical model
To verify our mathematical model, we validated Eq (9) by using leave-one-out cross-validation and leaving out one mutant per fold. We calculated the in silico conjugation capacity of AAP and E2 by using the docking results (S2 Table) , and we then compared the result with in vitro conjugation capacity (Fig 3A and 3B) . We found a significant correlation between in silico conjugation capacity and in vitro conjugation capacity ( Fig 3C) . On the basis of these results, we confirmed our mathematical model to be useful for predicting the conjugation capacity of mutant UGT1A1. Procedure for prediction of conjugation capacity in mutant UGT1A1
Validation of the experimental procedure: Prediction of the conjugation capacity of bilirubin and SN-38
We performed the docking analyses of UGT1A1 with bilirubin and SN-38 in the same manner as those for AAP and E2 (S2 Table) . The in silico conjugation capacities were calculated by inserting the docking results into Eq (9), and we then compared these results with the reported in vitro conjugation capacities [8, [38] [39] [40] [41] (Figs 4, 5A and 5B) . We found significant correlations between in silico and in vitro conjugation capacities ( Fig 5C) . These results indicate that our method for the prediction of conjugation capacity is valid in the tested cases of bilirubin and SN-38. Fig 6 indicates that our experimental procedure is effective for predicting the conjugation capacity, because all in silico results and in vitro results were significantly correlated. 
Discussion
Adverse drug reactions and differences in drug efficacies are often caused by mutations in drug metabolizing agents, drug targets, and drug transporters [42] . Recently, novel mutations causing amino acid substitutions have been found by genome analysis with high-throughput sequence technology [43] . These mutations cause quantitative reductions and loss of function in the enzymes [44] . Drug efficacy differences and adverse drug reactions generally do not occur without major mutations and polymorphism in promoter regions. If novel mutants are found, genetic information is unknown, and therefore genetic analysis is not used in a clinical therapeutic setting.
In this research, we developed in silico procedures that consists of a mathematical model and molecular simulation analyses, and we evaluated its validity. We strictly selected and specified software for molecular simulation and parameter settings to mimic the conjugation Procedure for prediction of conjugation capacity in mutant UGT1A1 process by UGT1A1, and the correctness of all modeled structures in this research was confirmed by the stable RMSD trajectory and low percentages in disallowed regions of Ramachandran plots.
To derive our mathematical model, we both performed docking analyses of UGT1A1 with the coenzyme or substrates (AAP and E2) and obtained the in vitro conjugation capacities of G71R, F83L. I322V, R336L, H376R, and P387S mutant of UGT1A1s. We compared in silico and in vitro results for two substrates to identify the key factors in this enzymatic reaction. We then found the number of hydroxyl orientations of substrate obtained from docking simulation analysis, which we identified as one feature (Fig 2, Table 1 ) that we previously identified as being a key assumption [5] . In our docking analysis using the AutoDock program, similar docking results were acquired by the docking program of MOE software. Moreover, we found the same feature with other UGT1A enzymes: UGT1A7 and UGT1A10 (S4 Fig). These results Procedure for prediction of conjugation capacity in mutant UGT1A1 suggest that the conjugation capacities of UGT1As are regulated by the number of hydroxyl orientations of the substrates. After our comparative analysis, we derived the mathematical model including the number of docking poses with correct binding, and it correctly determined the conjugation capacity of UGT1A1 mutants when conjugated with AAP and E2 (Fig 3) .
Finally, our procedure in silico, which consists of molecular simulation analyses and our mathematical model, was validated by its use for the glucuronidation of bilirubin and SN-38. We compared the calculated conjugation capacities in silico with reported conjugation capacities in vitro [8, [38] [39] [40] [41] . These predicted conjugation capacities closely approximated the reported in vitro findings ( Fig 5) . These results indicated that our mathematical model is valuable to predict the capacity of UGT1A1 to metabolize drugs. In this research, our procedure demonstrates the potential to predict the capacity of all UGT1A1 mutants based on Fig 6, which shows the data of the most studied mutants in vitro, and it also suggests that the same strategy may be available for other metabolic enzymes. This experimental procedure thus provides important information about adverse drug reactions for clinicians. 
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